The accompanying table presents the statistics and seven highest rated companies from the ETFI Global Cosmetic and Reconstructive Medicine [CRM] Index, which includes companies with market caps over $100M engaged in prescription skin care treatments, weight loss, cosmetic medicine, regenerative medicine, orthopedic repair, and joint replacements. Over the past year, the CRM Index fared better than the Healthcare Sector SPDR (XLV) and the S&P 500 SPDR (SPY) for the top 30 rated companies and all 50 companies included in the index.
Top rated companies profiled in the accompanying table include CryoLife (CRY) (biomaterials & tissue repair), Valeant Pharma (VRX) (skin care), Perrigo (PRGO) (skin care), Merit Medical Systems (MMSI) (products for obesity & medical devices), Exactech (EXAC) (orthopedic implants), Osiris Therapeutics (OSIR) (adult bone marrow derived stem cells for regenerative medicine), and Genzyme (GENZ) (Biosurgery business segment). The unique mix of companies in terms of market cap and business segments in the CRM Index allowed it to get through the past year relatively unscathed with a trailing 52-week average stock price change of -5.2% for the top 25 rated companies, compared to much higher losses for the overall market and the healthcare sector.
Top rated companies profiled in the accompanying table include CryoLife (CRY) (biomaterials & tissue repair), Valeant Pharma (VRX) (skin care), Perrigo (PRGO) (skin care), Merit Medical Systems (MMSI) (products for obesity & medical devices), Exactech (EXAC) (orthopedic implants), Osiris Therapeutics (OSIR) (adult bone marrow derived stem cells for regenerative medicine), and Genzyme (GENZ) (Biosurgery business segment). The unique mix of companies in terms of market cap and business segments in the CRM Index allowed it to get through the past year relatively unscathed with a trailing 52-week average stock price change of -5.2% for the top 25 rated companies, compared to much higher losses for the overall market and the healthcare sector.
$73.06 (11/01/08)
